Odanacatib pharmacokinetics in subjects with mild or moderate hepatic insufficiency and healthy controls

Trial Profile

Odanacatib pharmacokinetics in subjects with mild or moderate hepatic insufficiency and healthy controls

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2013

At a glance

  • Drugs Odanacatib (Primary)
  • Indications Male osteoporosis; Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 13 Nov 2013 New trial record
    • 08 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top